COMMUNIQUÉ DE PRESSE publié le 29/01/2024 à 12:30, il y a 9 mois 23 jours Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found NanoViricides, Inc. successfully completes Phase 1a/1b Clinical Trial of NV-CoV-2, reporting excellent safety and broad-spectrum antiviral activity of NV-387 against various respiratory viruses including Coronaviruses and RSV NV-387 NanoViricides Inc NV-CoV-2 Phase 1a/1b Clinical Trial Antiviral Therapy
COMMUNIQUÉ DE PRESSE publié le 04/01/2024 à 12:30, il y a 10 mois 17 jours NanoViricides to Present at the Biotech Showcase in San Fransisco NanoViricides, Inc., a leader in antiviral therapies based on nanomedicines technology, is set to present at the Biotech Showcase™ 2024 in San Francisco. The presentation will include an update on the successful Phase 1 clinical trials of NV-CoV-2 Oral Syrup and Oral Gummies, which contain the novel antiviral nanomachine NV-387. The company's President will discuss how NV-387 addresses the unmet need for a broad-spectrum antiviral drug as well as its potential across multiple virus families. With its wide spectrum of antiviral activity, NV-387 has the potential to revolutionize antiviral treatment, much like antibiotics did for bacterial infections. NanoViricides Antiviral Therapies NV-387 Biotech Showcase 2024 Broad-spectrum Antiviral Drug
COMMUNIQUÉ DE PRESSE publié le 28/11/2023 à 12:40, il y a 11 mois 23 jours The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides
COMMUNIQUÉ DE PRESSE publié le 15/11/2023 à 12:45, il y a 1 année NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications
COMMUNIQUÉ DE PRESSE publié le 14/11/2023 à 12:45, il y a 1 année Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development
COMMUNIQUÉ DE PRESSE publié le 16/10/2023 à 12:45, il y a 1 année 1 mois NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV
COMMUNIQUÉ DE PRESSE publié le 12/10/2023 à 12:45, il y a 1 année 1 mois NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET
COMMUNIQUÉ DE PRESSE publié le 21/08/2023 à 12:45, il y a 1 année 3 mois The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides
COMMUNIQUÉ DE PRESSE publié le 11/07/2023 à 12:45, il y a 1 année 4 mois Company’s Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides
COMMUNIQUÉ DE PRESSE publié le 06/07/2023 à 12:45, il y a 1 année 4 mois Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs
Publié le 21/11/2024 à 06:58, il y a 11 heures 51 minutes Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 11 heures 51 minutes Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 11 heures 51 minutes Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Publié le 20/11/2024 à 20:07, il y a 22 heures 42 minutes Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Publié le 20/11/2024 à 19:20, il y a 23 heures 29 minutes Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Publié le 21/11/2024 à 17:35, il y a 1 heure 14 minutes 1upHealth Ranked Number 43 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500(TM)
Publié le 21/11/2024 à 17:30, il y a 1 heure 19 minutes SimpliGov and Proof Partner to Offer Online Notarization
Publié le 21/11/2024 à 16:30, il y a 2 heures 19 minutes The Rise of DINKs: Dual-Income Couples Without Kids Redefine Financial Priorities in America
Publié le 21/11/2024 à 16:01, il y a 2 heures 48 minutes Career Certified Extends Its Investment in the Fast-Growing Architecture, Engineering, and Construction (AEC) Professionals Market with Acquisition of My Contractors License
Publié le 21/11/2024 à 16:00, il y a 2 heures 49 minutes Financial Independence Group Announces Exclusive Partnership With Power of Zero and Tax-Free Retirement Expert David McKnight
Publié le 21/11/2024 à 18:36, il y a 13 minutes Original-Research: Beaconsmind AG (von First Berlin Equity Research GmbH): BUY
Publié le 21/11/2024 à 17:51, il y a 58 minutes LIGHTON announces highly successful IPO on Euronext Growth Paris.
Publié le 21/11/2024 à 17:51, il y a 58 minutes LIGHTON annonce le vif succès de son introduction en Bourse sur Euronext Growth Paris.
Publié le 21/11/2024 à 17:51, il y a 58 minutes 2CRSi SA: 2CRSi supplies Exaion, a subsidiary of the EDF Group, with high-performance immersion servers in North America.